Some exciting news to share – The Isaac Foundation spent the entire month of June ensuring continued access to Vimizim for our Canadian Clinical Trial patients suffering from Morquio A Syndrome.
The compassionate use program, which saw all patients who participated in the Vimizim clinical trial receive access to therapy for a certain period of time, was set to end on June 30, 2016. This would have resulted in the remaining 11 patients losing access to their much needed treatment until it was fully reimbursed by the government.
Working collaboratively with the Ministry of Health in Ontario and with Biomarin pharmaceuticals, I’m thrilled to report that we’ve been able to ensure access to treatment for all 11 patients until Biomarin and Canadian Provinces (pCPA) can negotiate terms and conditions for coverage for all patients. Both Biomarin and the government did fantastic work on this, and we’re thrilled with the outcome.
We will continue to do everything we can to help patients and their families receive the best care possible as they battle this and other ultra-rare diseases. Thanks to everyone for supporting us and helping along the way.